Global Bulimia Nervosa Market Research Report: Information by Disorder Type (Purging and Non-Purging), Drug Type (Antidepressants, Antipsychotics, and Others), Route of Administration (Oral, Intravenous, and Others), End User (Hospitals & Clinics, Homecare Settings, Specialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025
Market Research Future (MRFR) expects the global Bulimia Nervosa Market to achieve a CAGR of 4.5% during the forecast period (2017-2023).
Market Drivers and Top Risks
Bulimia nervosa is described as a serious eating disorder indicated by frequent incidents of binge eating as an extreme effort to avoid gaining weight. These efforts are in the form of vomiting or exercising excessively. Eating disorder is identified as a mental health issue, which leads to extreme and dangerous eating behavior. Bulimia nervosa can be brought on by cardiovascular & diabetes disease or alcoholism. It is widespread among females than in males.
The bulimia nervosa market could project robust growth in the near future backed by changing life style and increasing consumption of alcohol. Rise in mental health disorders, surge in diabetes and cardiovascular disease cases, and mounting awareness about healthcare has led to significant market traction in recent years. Numerous vendors within the developing markets are expanding their reach, supported by a strong pipeline of product and services. Based on this, data experts estimate that the market holds high potential and is set to have a lucrative run during the forecast period.
Cases of bulimia nervosa in the United States (U.S) has been reported to be more than 1.5% among women and 0.5% among men, which translates to more than 4.5 million women and 1.5 million men. The burden of the disease is prevalent among adolescents; however, it has also been diagnosed among those as young as six years as well as in adults. The uptake of alcohol, along with the rising number of cardiovascular diseases has resulted in the expansive market coverage across the globe.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/1417
The global bulimia nervosa market has been segmented on the basis of type of treatment, which is further segmented into drug therapy, psychotherapy, and other. Psychotherapy types are Maudsley family therapy and others, and the types of drug therapy include antidepressants and others.
Asia Pacific, North America, Middle East & Africa and Europe are the main markets for bulimia nervosa.
North America is the leading bulimia nervosa market with the rising prevalence of the disorder. It is reported that in the region, close to 6.2 million people suffer from bulimia nervosa with the majority being young adults. Besides, unmet demand for medication coupled with technological advancements works in favor of the regional market. High awareness levels regarding eating disorders in the region benefit the market as well, as more people are now willing to get treatment.
In Europe, awareness about bulimia nervosa is now entering the public consciousness, with the field now receiving high research and development (R&D) attention. A host of latest drugs are in the later stage of development with researchers striving to untangle the metabolic and psychological aspects of this condition. This goes hand in hand with the rising healthcare expenditure, which works wonders for the regional market.
A paradigm shift has been noted for bulimia nervosa in Asia Pacific, triggered by the conceptualization of bingeing behavior touted to as an addiction disorder. This has resulted in a wave of interest in high-quality drugs. With the constant struggle between the need for effective treatments and rising cases of bulimia nervosa in APAC, healthcare professionals now realize the urgent need for extra research in this area. On this basis, MRFR expects Asia Pacific to be the fastest-expanding market for bulimia nervosa in the given timeframe.
Middle East & Africa account for the smallest market for bulimia nervosa. But the market could get some respite from the expanding diet industry as well as the rising popularity of social media.
Browse Complete Toc :https://www.marketresearchfuture.com/reports/bulimia-nervosa-market-1417
Abbott (U.S), Johnson & Johnson Services, Inc. (U.S), Philips Healthcare (U.S), General Electric Company (U.K), Siemens Healthcare GmbH (Germany), Covidien Ltd (Ireland), Penumbra, Inc. (U.S), Stryker (U.S), are some of the leading companies shaping the global bulimia nervosa market.